This website uses cookies
Read our Privacy policy and Terms of use for more information.
May 4, 2026
Insulet has enrolled its first participant in its EVOLVE trial testing an automated system designed to eliminate mealtime bolus announcements for people with type 2 diabetes.
Apr 28, 2026
Sanofi's disease-modifying therapy can now be used in children as young as 1 year old, opening a new window to delay type 1 diabetes progression in the youngest patients.
Apr 14, 2026
Niia Essential demonstrated proof of concept, strong performance and accuracy, and zero insulin delivery failures in its first clinical study.
Mar 17, 2026
During the conference, Dexcom showcased upcoming device updates, new platform features, and future innovations designed to expand and enhance its CGM ecosystem.
Mar 16, 2026
A bill stalled in Congress and a promising clinical trial may together be the most important developments in type 1 diabetes treatment right now.
Mar 12, 2026
Results from the EVOLUTION 2 trial presented at ATTD showed 68% time in range using a fully closed-loop system—with no mealtime boluses and minimal time below range.
Feb 23, 2026
Encapsulated neonatal pig islet cells, implanted without immunosuppression in the OPF-310 trial, cut a type 1 diabetes patient’s insulin needs in half at six months, with further maturation expected.
Feb 17, 2026
We spoke with an FDA-insider about how the organization regulates diabetes tech and how recent political events have shaken up the agency.
Feb 12, 2026
MannKind’s INHALE‐1ST trial is testing an inhaled insulin, as a needle‐free option for children with type 1 diabetes with an expected FDA decision by May 29, 2026.
